A carrier-free supramolecular nano-twin-drug for overcoming irinotecan-resistance and enhancing efficacy against colorectal cancer

Irinotecan (Ir) is commonly employed as a first-line chemotherapeutic treatment for colorectal cancer (CRC). However, tremendous impediments remain to be addressed to surmount drug resistance and ameliorate adverse events. Poly-ADP-Ribose Polymerase (PARP) participates in the maintenance of genome s...

Descripción completa

Detalles Bibliográficos
Autores principales: Yuan, Miaomiao, Chen, Tong, Jin, Lu, Zhang, Peng, Xie, Luoyijun, Zhou, Shuyi, Fan, Lianfeng, Wang, Li, Zhang, Cai, Tang, Ning, Guo, LiHao, Xie, Chengmei, Duo, Yanhong, Li, Ling, Shi, Leilei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10612220/
https://www.ncbi.nlm.nih.gov/pubmed/37898773
http://dx.doi.org/10.1186/s12951-023-02157-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10612220/
https://www.ncbi.nlm.nih.gov/pubmed/37898773
http://dx.doi.org/10.1186/s12951-023-02157-x

Ejemplares similares